Compare Cintas Corporation (CTAS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Smith & Nephew plc — how do they compare? Cintas Corporation trades at $204.95 (market cap $82.15B), while Smith & Nephew plc trades at $29.75 (market cap $12.54B). The key difference: Cintas Corporation is far larger — about 6.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| CTAS | SNN | |
|---|---|---|
Market Cap | $82.15B | $12.54B |
Sector | Industrials | Health |
52-Week High | $225.10 | $38.70 |
52-Week Low | $163.55 | $28.73 |
Enterprise Value | $84.56B | $15.57B |
Dividend Yield | 1.01% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTAS trades at $203.06, showing modest daily gains. The stock exhibits a bullish technical trend, supported by recent earnings beats and strong profitability metrics, including a 17.75% net income margin. Recent news highlights dividend declarations and positive analyst upgrades following Q4 2026 results.
The outlook is positive, with revenue growth and margin expansion driving upside potential toward the $225.83 consensus price target. Risks include elevated valuation multiples and macroeconomic sensitivity. Institutional activity shows mixed positioning, but overall sentiment leans bullish.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
